Co-prescriptions with itraconazole and fluconazole as a signal for possible risk of drug-drug interactions: A four-year analysis from Italian general practice

Pharmacoepidemiology and Drug Safety

Volumn 16, Issue 4, 2007, Pages 422-428

  Galatti, Laura ^a   Mazzaglia, Giampiero ^b   Greco, Antonella ^c   Sessa, Emiliano ^b   Cricelli, Claudio ^c   Schito, Grian Carlo ^d   Nicoletti, Giuseppe ^e   Spina, Edoardo ^a   Caputi, Achille P ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b Health Search Database   (Italy)

^c Italian College of General Practitioners   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e UNIVERSITY OF CATANIA   (Italy)

Author keywords

Drug drug interactions; Fluconazole; General practice; Itraconazole

Indexed keywords

ALPRAZOLAM; AMLODIPINE; ATORVASTATIN; BENZODIAZEPINE DERIVATIVE; BROMAZEPAM; CALCIUM CHANNEL BLOCKING AGENT; CISAPRIDE; CLARITHROMYCIN; DELORAZEPAM; DIAZEPAM; DIGOXIN; DILTIAZEM; ETHINYLESTRADIOL PLUS GESTODENE; FELODIPINE; FLUCONAZOLE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; LACIDIPINE; LERCANIDIPINE; LEVONORGESTREL; METHYLPREDNISOLONE; MIZOLASTINE; NIFEDIPINE; PHENYTOIN; PRAVASTATIN; RIFAMPICIN; SIMVASTATIN; THEOPHYLLINE; UNINDEXED DRUG; VERAPAMIL;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DERMATOMYCOSIS; DRUG COMPETITION; DRUG MONITORING; DRUG USE; FEMALE; GENERAL PRACTICE; HUMAN; INFORMATION PROCESSING; ITALY; MAJOR CLINICAL STUDY; MALE; MYCOSIS; ONYCHOMYCOSIS; PHARMACEUTICAL CARE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; DATABASES; DRUG INTERACTIONS; DRUG UTILIZATION; FAMILY PRACTICE; FEMALE; FLUCONAZOLE; HUMANS; ITALY; ITRACONAZOLE; MALE; MIDDLE AGED; MYCOSES; ODDS RATIO; PHYSICIAN'S PRACTICE PATTERNS; POLYPHARMACY; PRESCRIPTIONS, DRUG; RISK ASSESSMENT; TIME FACTORS;

EID: 34247546564     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1389     Document Type: Article

References (36)

1. Morera T, Gervasini G, Carrillo JA, et al. Using a computerized drug prescription screening system to trace drug interactions in an outpatient setting. Ann Pharmacother 2004; 38: 1301-1306. DOI: 10.1345/aph.1D549.
2. Shapiro LE, Shear NH. Drug interactions: proteins, pumps, and P-450s. J Am Acad Dermatol 2002; 47:467-484. DOI: 10.1067/ mjd.2002.126823.
3. Lin JH. Sense and nonsense in the prediction of drug-drug interactions. Curr Drug Metab 2000; 1: 305-331.
4. du Souich P. In human therapy, is the drug-drug interaction or the adverse drug reaction the issue? Can J Clin Pharmacol 2001; 8: 153-161.
5. Gallagher LP. The potential for adverse drug reactions in elderly patients. Appl Nurs Res 2001; 14: 220-224. DOI: 10.1053/ apnr.2001.26788.
6. Shapiro LE, Shear NH. Drug-drug interactions: how scared should we be? CMAJ 1999; 161: 1266-1267.
7. Linnarsson R. Drug interactions in primary health care. A retrospective database study and its implications for the design of a computerized decision support system. Scand J Prim Health Care 1993; 11: 181-186.
8. Bjerrum L, Andersen M, Petersen G, et al. Exposure to potential drug interactions in primary health care. Scand J Prim Health Care 2003; 21: 153-158. DOI: 10.1090/02813430310001806.
9. Bergendal L, Friberg A, Shafftrat A. Potential drug-drug interactions in 5,125 mostly elderly out-patients in Gothenburg, Sweden. Pharm World Sci 1995; 17: 152-157. DOI: 10. 1007/BF01879709.
10. Bates DW, Yu DT. Clinical impact of drug-drug interactions with systemic azole antifungals. Drugs Today (Barr) 2003; 39: 801-813.
11. Pea F, Furlanut M. Phsirmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions. Clin Pharmacokinet 2001; 40: 833-868.
12. Filippi A, Bignamini AA, Sessa E, et al. Secondary prevention of stroke in Italy: a cross-sectional survey in family practice. Stroke 2003; 34: 1010-1014. DOI: 10.1161 /01.STR.0000062888.90293AA.
13. Filippi A, Sabatini A, Badioli L, et al. Effects of an automated electronic reminder in changing prescribing behaviour among General Practitioners in Italy: an intervention trial. Diabetes Care 2003; 26: 1497-1500.
14. World Health Organisation. Statistical Classification of Diseases: Injuries and Cause of Death, Vols. 1,2. WHO: Geneva, 1977.
15. Charlson ME, Pompei P, Ales KI, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383.
16. Summary of the product characteristics: sporanox, itraconazole. Janssen Cilag, Cologno Monzese (Ml) - Italy, (revised 5/2002).
17. Summary of the product characteristics: diflucan, fluconazole. Pfizer, Borgo san Michele (Latina) - Italy (revised 9/2003).
18. Summary of the product characteristics: sporanox, itraconazole. Janssen Cilag, Cologno Monzese (MI) - Italy, (revised 1/2000).
19. Summary of the product characteristics: diflucan, fluconazole. Pfizer, Borgo san Michele (Latina) - Italy (PI revised 5/2000).
20. Malone DC, Hutchins DS, Haupert H, et al. Assessment of potential drug-drug interactions with a prescription claims database. Am J Health Syst Pharm 2005; 62: 1983-1991.
21. Osservatorio nazionale sull'impiego dei farmaci. L'uso dei farmaci in Italia. Rapporto nazionale anno 2002; 48.
22. Gupta AK, Ryder JE, Skinner AR. Treatment of onychomycosis: pros and cons of andfungal agents. J Cutan Med Surg 2004; 8: 25-30. DOI: 10.1007/s10227-003-0109x.
23. Sagir A, Schmitt M, Dilger K, et al. Inhibition of cytochrome P450 3A: relevant drug interactions in gastroenterology. Digestion 2003; 68: 41-48. DOI: 10.1159/000073224.
24. Debruyne D, Coquerel A. Pharmacokinetics of antifungal agents in onychomycoses. Clin Pharmacokinet 2001; 40: 441-472.
25. Paille F. Over-consumption of drugs by elderly patients. Therapie 2004; 59: 215-222.
26. Klotz U. Interaction potential of lercanidipine, a new vasoselective dihydropyridine calcium antagonist. Arzneimittelforschung 2002; 52: 155-161.
27. Kim HJ, Choi JS. Effects of naringin on the pharmacokinetics of verapamil and one of its metabolites, norverapamil, in rabbits. Biopharm Drug Dispos 2005; 26: 295-300. DOI: 10.1002 /bdd.459.
28. Jalava KM, Olkkola KT, Neuvonen PJ. Itraconazole greatly increases plasma concentrations and effects of felodipine. Clin Pharmacol Ther 1997; 61: 410-415.
29. Paoletti R, Corsini A, Bellosta S. Pharmacological interactions of statins. Atheroscler Suppl 2002; 3: 35-40. DOI: 10.1016/ S1567-5688(02)00002-8.
30. Shaukat A, Benekli M, Vladutiu GD, et al. Simvastatin-fluconazole causing rhabdomyolysis. Ann Pharmacother 2003; 37: 1032-1035. DOI: 10.1345/aph.1C467.
31. Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002; 41: 343-370.
32. Hilbert J, Messig M, Kuye O, et al. Evaluation of interaction between fluconazole and an oral contraceptive in healthy women. Obstet Gynecol 2001; 98: 218-223.
33. Sinofsky FE, Pasquale SA. The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives. Am J Obster Gynecol 1998; 178: 300-304.
34. Ahonen J, Olkkola KT, Takala A, et al. Interaction between fluconazole and midazolam in intensive care patients. Acta Anaesthesiol Scand 1999; 43: 509-514.
35. Sawamura R, Sato H, Kawakami J, et al. Inhibitory effect of azole antifungal agents on the glucuronidation of lorazepam using rabbit liver microsomes in vitro. Biol Pharm Bull 2000; 23: 669-671.
36. Yu DT, Peterson JF, Seger DL, et al. Frequency of potential azole drug-drug interactions and consequences of potential fluconazole drug interactions. Pharmacoepidemiol Drug Saf 2005; 14: 755-767. DOI: 10.1002/pds.1073.